By John Chubak, MD, FACS

As a board-certified cardiovascular surgeon specializing in venous and lymphatic disease, I firmly believe that the introduction of micronized purified flavonoid fraction (MPFF) into the U.S. market represents perhaps the most important innovation in daily practice we’ve seen in the last 10 years. This advancement is crucial for supporting venous and lymphatic function by preventing inflammatory sequela and microcirculatory dysfunction caused by venous hypertension (Figure 1). Venous or lymphatic disorders are believed to affect 50% of U.S. citizens, creating a substantial public health burden.

MPFF, a dietary supplement, has garnered significant recognition, being recommended in all clinical practice guidelines from esteemed organizations such as the Society for Vascular Surgery, the American Vein and Lymphatic Society, and the American Venous Forum. These endorsements underscore its efficacy and safety, marking a pivotal paradigmatic shift in philosophy.

The benefits of MPFF are manifold. It not only helps support vein function in patients with chronic venous insufficiency, but also supports overall vascular health. By improving microcirculation and reducing inflammation through its antioxidant mechanism of action, MPFF aids in the prevention of more severe complications, ultimately enhancing patients’ quality of life.

Vein Formula and Lymphatic Formula, introduced by VitasupportMD, are simple to incorporate into daily routines and act as excellent adjuncts to other standard treatments. This innovation aligns with our ongoing efforts to provide holistic care, emphasizing patient well-being and compliance.

The availability and guideline endorsement of MPFF in the U.S. is a significant step forward in the management of the venous and lymphatic systems and reinforce the importance of improving patient outcomes by providing a comprehensive approach to care, which includes systemic dietary supplements.

John Chuback, MD, FACS, is co-founder of VitasupportMD in Paramus, NJ.